細胞治療の世界市場

【英語タイトル】Global Cell Therapy Market, Therapy Price, Dosage and Clinical Trials Insight 2027

Kuick Researchが出版した調査資料(HNI908SP2842)・商品コード:HNI908SP2842
・発行会社(調査会社):Kuick Research
・発行日:2020年6月
・ページ数:150
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2営業日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,300 ⇒換算¥343,200見積依頼/購入/質問フォーム
Multi-User(法人閲覧用)USD5,100 ⇒換算¥530,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

“Global Cell Therapy Market, Therapy Price, Dosage and Clinical Trials Insight 2027″ Report Highlights:

* Global Cell Therapy Market Opportunity: More Than USD 40 Billion By 2027
* Cell Therapy Clinical Trial Insight by Indication, Company and Country
* Global Cell Therapy Clinical Pipeline: 1000 Cell Therapies
* Globally Marketed Cell Therapies: 25 Cell Therapies
* Cell Therapy Trials For COVID-19: 10 Cell Therapies
* Global COVID-19 Cell Therapy Clinical Trials By Phase and Company
* COVID-19 Impact Analysis on Global market and Clinical Trials
* Price and Product Insight By Region/Country

Over a period of time, cell therapy has emerged as next growth frontier for the pharmaceutical companies involved the research and development of innovative therapies for the treatment of simple to complex medical anomalies. The increasing focus on new technologies and methodologies are leading to path breaking innovations which are playing an important role in the practice of medicine and cell therapy. The cell therapy approach to treatment and prevention is more advanced and targeted as compare to traditional therapies as the former works at basic level on human science that is cells. Cell therapy treatment is more advanced and custom in nature and thus giving the required thrust to advancement of personalized therapy.

“Global Cell Therapy Market Opportunity To Surpass US$ 40 Billion by 2027 Driven By Robust Clinical Pipeline and Increasing Sales Of Therapies Like Yescarta and Kymriah”

Cell therapy research and clinical advancement has accelerated strongly in the limited period of time. Once limited to bone marrow transplants, the cell therapy field is currently prepared to achieve critical advances in various distinctive clinical signs. The same scenario can be reflected in the fact that the number of clinical trials have increased more than 50% in last 2 years. At present (June’2020), more than 1000 cell therapies are in pipeline and 25 therapies are commercially available in the market. Most of the cell therapies are in preclinical stage and close to 450 therapies are in Phase I, Phase II and Phase III trials. Analysis of the pipeline shows that the majority of cell therapy products that are currently under development are targeted towards treatment of complex disease like cardiovascular disease, neural disease and cancer.

The commercial acceptability and success of cell therapies can also be reflected from robust sales of therapies like Yescarta (Gilead Sciences) and Kymriah (Novartis). During 2019, the sales of Yescarta surpassed US$ 450 Million as compared to US$ 264 Million in 2018, with annual growth of almost 72%. Similarly, Kymriah witnessed growth of 260% with total sales of more than US$ 270 Million in 2019 as compare to less than US$ 75 Million in 2018. Further, the rapid approval and orphan status of few therapeutics coming out of the cell therapy pipeline ensures it to be a lucrative segment. Several collaborations in the past few years has created an optimistic scenario when it comes to the future of cell therapy segment. The cell therapy industry is rapidly growing industry with the several new products that having been accepted for clinical use over the past few years. There are many challenges that need to be resolved wisely before the cell therapies are widely accepted, including the optimization of their manufacture.

With increasing number of clinical trials, robust sales values and widening clinical indication base, it is clear reflection of the fact that the cell therapy market will witness remarkable growth trajectory in coming years. The global cell therapy market opportunity is estimated to surpass US$ 40 Billion by 2027 driven by increasing technical and manufacturing capabilities coupled with the advancements that will drive the acceptability of cell therapy procedures among the various stakeholders of the pharmaceutical industry. The current scenario of COVID-19 may slowdown the clinical trials conductibility or the market growth trajectory but the same COVID-19 pandemic is going to offer new growth avenues to the industry in form of ongoing clinical trials for the treatment of COVID-19.

【レポートの目次】

1. Overview of Cell Therapy
1.1 Introduction to Cell Therapy
1.2 History and Evolution of Cell Therapy

2. Cell Therapy Classification
2.1 Allogeneic Cell Therapy
2.2 Autologous Cell Therapy
2.3 Human Embryonic Stem Cell Therapy
2.4 Neural Stem Cell Therapy
2.5 Mesenchymal Stem Cell Therapy
2.6 Hematopoietic Stem Cell Transplantation

3. Mechanism of Therapeutic Action in Cell Therapy

4. Manufacturing of Cell Therapies
4.1 Models for Manufacturing Cell Therapies
4.2 Facilities for Good Manufacturing Practice

5. Advantages of Cell Therapy Over Conventional Therapy
5.1 Anti-Aging with Cell Therapy
5.2 Addressing Other Diseases with Cell Therapy

6. Emergence of Personalized Cell Therapy
6.1 Overview of Personalized Cell Therapy
6.2 Personalized Cell Therapy Using Epigenetic Tools
6.3 Personalized Cell Therapy through Mesenchymal Stem Cells
6.4 Treatment of Parkinson’s Disease through IPSCs
6.5 Case Study: Personalized Cell Therapy for Pulpitis Using Autologous Dental Pulp
Stem Cells and Leukocyte Platelet Rich Fibrin

7. Cell Therapy Application by Therapeutic Areas
7.1 Cardiovascular Disease
7.2 Neurological Disorders
7.3 Inflammatory Diseases
7.4 Diabetes

8. Application of Cell Therapy to Cancer Therapeutics
8.1 Stem Cells and Their Therapeutic Role in Cancer
8.2 Role of Surface Markers and Their Targeting

9. Cell Therapy Research Insights at University Level
9.1 Cell Therapy for Diabetes in Animal Model
9.2 Cell Therapy as a Renewable Treatment Source for Cancer
9.3 Advancing CAR T-Cell Therapy for Cancer Treatment
9.4 Improving Depth and Durability of Cancer Treatment by CAR T – Cell Therapy
9.5 NKTR-214 in Combination with Adoptive Cell Therapy Against Melanoma
9.6 Regenerative Medicine Advanced Therapy Designation Granted to CAR T-Cell
Therapy by FDA
9.7 UCLA and CASIS Collaboration for Regenerative Medicine and Stem Cell Research
9.8 Dual Stem Cell Therapy for Cardiac Repair
9.9 T-Cell Therapy against Multiple Forms of Cancers
9.10 Stem Cell Therapy against Covid-19 Pandemic
9.11 AgeX Therapeutics and University of California Research Program for Huntington’s
Disease and Other Neurological Disorders
9.12 Avacta Group plc and Memorial Sloan Kettering Cancer Center Research
Collaboration for CAR-T Cell – Based Immunotherapy.
9.13 Remodeled CAR-T Cell Therapy Undergoing Extensive Groundwork
9.14 Invariant Natural Killer Cell’s Long-Lasting Immunity against Cancer Cells
9.15 Light Sensitive CAR-T Cells against Skin Tumor in Mice Resulted to be Effective
9.16 Scorpion Toxin to Guide CAR-T Cells for Brain Cancer

10. Strateging Alliances for Promoting Cell Therapy Research
10.1 GlaxoSmithKline’s Deal with Immatics Cell Therapy Science to Advance Cell
Therapy
10.2 Indapta Therapeutics and Lonza’s New Partnership for Advancing Cancer Cell
Therapy
10.3 Key Biologics and Blood Centers of America to Open Access for Cell Therapy
10.4 Gamida Regulatory Nods with Lonza for Cell Therapy Product Production
10.5 GlaxoSmithKline and Lyell Immunopharma to Develop Next Generation Cancer Cell
Therapies
10.6 Harvard and MIT to Bolster Cell and Gene Therapy Medical Research
10.7 Takeda and MD Anderson to Accelerate the Development of NK Cell Therapy
Platform
10.8 Multiple Cell Therapy Collaborations Initiated by Takeda Pharmaceuticals
10.9 Mesenchymal Stem Cell Program Launch By Celltex against Covid-19
10.10 Artisan Bio Announces Global Research and Takeda to Undergo Next-Generation
Cell Therapy Products Development
10.11 Astellas and Universal Cells, Inc. Collaboration for Cell Therapy Product
Development for Undisclosed Indication
10.12 Fate Therapeutics and Janssen to Undergo Worldwide Collaboration for iPSC-
derived Cell-based Cancer Immunotherapies
10.13 Kite and Teneobio Collaboration for the Development of CAR-T Antibodies
10.14 Lonza to Undergo Series of Collaborations for the Development of Novel Cell
Cancer Therapies
10.15 Other Latest Press Releases for Stem Cell Therapy Research and Development
10.15.1 RegenMed Development Organization and CollPlant Business Alliance
10.15.2 Institute of Integrative Biology and Anika Therapeutics Business Alliance
10.15.3 The US FDA and Cytobank Collaboration Agreement

11. Global Cell Therapy Clinical Pipeline Overview
11.1 By Phase
11.2 By Country/Region
11.3 By Company
11.4 By Indication
11.5 By Patient Segment
11.6 By Route Of Administration

12. Impact of COVID-19 On Cell Therapy Research Landscape

13. Global COVID-19 Cell Therapy Clinical Trials By Phase and Company
13.1 Research
13.2 Preclinical
13.3 Clinical
13.4 Phase-I
13.5 Phase-I/II
13.6 Phase-II

14. Global Cell Therapies Clinical Pipeline By Company, Indication and Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-0
14.6 Phase-I
14.7 Phase-I/II
14.8 Phase-II
14.9 Phase-II/III
14.10 Phase-III
14.11 Preregistration
14.12 Registered

15. Global Cell Therapy Market Outlook
15.1 Current Market Scenario
15.2 Cell Therapy Market by Cell Source
15.2.1 Induced Pluripotent Stem Cell (IPSCs)
15.2.2 Bone Marrow
15.2.3 Umbilical Cord Blood Derived Cells

16. US – Cell Therapy Dosage and Cost Analysis
16.1 Allocord
16.2 Laviv
16.3 Maci
16.4 Clevecord
16.5 Hemacord
16.6 Ducord
16.7 Provenge
16.8 HPC, Cord Blood (Clinimmune Labs, University of Colorado Cord Blood Bank)
16.9 HPC, Cord Blood (LifeSouth Community Blood Centers, Inc)
16.10 HPC, Cord Blood (Bloodworks)
16.11 HPC, Cord Blood (MD Anderson Cord Blood Bank)
16.12 Gintuit
16.13 Kymriah*
16.14 Yescarta*
16.15 Carticel

17. South Korea – Cell Therapy Dosage and Cost Analysis
17.1 Cartistem
17.2 Chondron
17.3 KeraHeal
17.4 Cellgram
17.5 Cure Skin Injection

18. Australia, Europe and Japan – Cell Therapy Dosage and Cost Analysis
18.1 Holoclar (Europe)
18.2 Yescarta (EU)
18.3 Kymriah (EU)
18.4 Temcell HS (Japan)
18.5 Chondrocytes-T-Ortho-ACI (Australia)

19. Global Cell Therapy Market Scenario
19.1 US
19.2 South Korea
19.3 Europe
19.4 Japan
19.5 China
19.6 Rest of the World

20. Global Cell Therapy Research Advancements
20.1 Drug Based Therapies Advancements in Chronic Lymphocytic Leukemia
20.2 Advances in Cytomegalovirus Infection Prevention and Treatment
20.3 Stem Cell Therapy for the Treatment of Parkinson’s Disease
20.4 Stem Cell Therapy for the Treatment of Alzheimer’s Disease
20.5 Treatment of Rheumatoid Arthritis via Stem Cell Therapy
20.6 Role of Stem Cell Therapy in Treating Infertility
20.7 Stem Cells for Eye Diseases
20.8 Cell Therapy for Stroke and Angina Pectoris
20.9 Stem Cell Therapy in Improving Wrinkles and Acne Scars

21. Treg Cells – The Next Step To Advance Cell Therapy
21.1 Introduction to Treg Cell
21.2 Isolation and Expansion of Treg Cell
21.3 Mechanism of Action
21.4 Clinical Trials of Treg Cell Therapy
21.4.1 Adoptive Cell Therapy of Treg cells to Prevent GvHD
21.4.2 Adoptive Cell Therapy of Polyclonal and Alloantigen-specific Treg cells to
Prevent Solid Organ Transplant Rejection
21.5 Treg Cell Therapy for the Treatmet of Autoinflammatory and Autoimmune
Diseases
21.5.1 Inflammatory Bowel Disease
21.5.2 Systemic Lupus Erythematosus
21.5.3 Autoimmune Hepatitis
21.5.4 Pemphigus Vulgaris
21.5.5 Allergy and Asthma
21.6 Future Prospects of Treg Cell Therapy

22. Global Cell Therapy Market Future Prospects

23. Marketed Cell Therapies Clinical Insight by Company and Indication
23.1 Tisagenlecleucel (Kymriah)
23.2 Axicabtagene Ciloleucel (Yescarta)
23.3 Allogeneic Cultured Keratinocytes And Fibroblasts (Gintuit)
23.4 Adipose Stem Cell Therapy (Adipocell (Anterogen), Cupistem and Queencell)
23.5 Tonogenchoncel-L (INVOSSA-K inj)
23.6 Mesenchymal Stem Cell Therapies (Stempeucel)
23.7 Remestemcel-L (Prochymal and TEMCELL HS Inj.)
23.8 Sipuleucel-T (Provenge)
23.9 Autologous Mesenchymal Stem Cell Therapy – Pharmicell
23.10 Autologous Cultured Chondrocytes (MACI)
23.11 Autologous Cultured Chondrocytes (Chondrotransplant DISC)
23.12 Autologous Corneal Epithelial Stem Cell Therapy (Holoclar)
23.13 Nalotimagene Carmaleucel (Zalmoxis)
23.14 Mesenchymal Stem Cell Therapy For Cartilage Repair (Cartistem)
23.15 Autologous Chondrocyte Implant – TETEC
23.16 Muscle-Derived Autologous Stem Cell Therapy (MyoCell)
23.17 Human Skin Replacement (CellSpray)
23.18 Leukocyte Cell Therapy (CureXcell)
23.19 Autologous Cultured Chondrocyte Implant (Carticel)
23.20 Azficel-T (Laviv)
23.21 Autologous Cultured Chondrocytes (CHONDRON)
23.22 Autologous Chondrocytes (BioCart)
23.23 Amniotic Cell Therapy (NuCel)
23.24 Dendritic Cell-Activated Cytokine-Induced Killer Cells – Shanghai Jia Fu Medical
23.25 Autologous Cultured Myoblasts And Fibroblasts (Urocell)

24. Competitive Landscape
24.1 Athersys Inc.
24.2 Baxter Healthcare Corporation
24.3 Bone Therapeutics
24.4 Celgene Corporation
24.5 Cell Medica
24.6 Cellerant Therapeutics
24.7 FibrocellScinence
24.8 Genzyme Corporation
24.9 Green Cross Cell
24.10 Histogenics Corporation
24.11 Intrexon Corporation
24.12 Intercytex
24.13 ISTO Biologics
24.14 Macrocure
24.15 Mesoblast
24.16 Molmed
24.17 Nuo Therapeutics Inc
24.18 OmniCyte
24.19 Opexa Therapeutics
24.20 Organogenesis
24.21 Pharmicell
24.22 TCA Cellular Therapy
24.23 Stem Cell Inc.
24.24 Teva Pharmaceuticals
24.25 Tigenix
24.26 Vericel Corporation

Figure 1-1: Cell Therapy Pathway
Figure 1-2: Evolution of Cell Therapy

Figure 2-1: Types of Cell Therapy
Figure 2-2: Steps in Allogeneic Cell Therapy
Figure 2-3: Steps in Autologous Cell Therapy
Figure 2-4: Steps in the Derivation of Human Embryonic Stem Cells
Figure 2-5: Cardinal Neural Stem Cell Properties
Figure 2-6: Mesenchymal Stem Cells Therapy Process

Figure 3-1: Cell Therapy Mechanism

Figure 4-1: Centralized Manufacturing Model
Figure 4-2: Near Patient Manufacturing Model

Figure 5-1: Major Steps in Cell Therapy
Figure 5-2: Global- Expected Aging Population of 60+ (Billion), 2015 and 2050
Figure 5-3: Advantages of Cell Therapy as a Rejuvenation Therapy

Figure 6-1: Advantages of Personalized Cell Therapy
Figure 6-2: Mesenchymal Stem Cells (MSCs) in Autism Spectrum Disorder (ASD)
Treatment
Figure 6-3: Steps of iPSC Transplantation

Figure 7-1: Global – Mortality Caused by Non Communicable Disease (%)
Figure 7-2: Cell Therapy for Cardiovascular Disease
Figure 7-3: Overview of Stem Cell Therapy in Cardiovascular Disease
Figure 7-4: Cell Therapy in Neurological Disorders
Figure 7-5: Cell Therapy in Treatment of Alzheimer’s disease
Figure 7-6: Cell Therapy in Diabetes

Figure 9-1: Clinical Trial Results, February’2020
Figure 9-2: Clinical Trial Results (%), February’2020

Figure 11-1: Global – Cell Therapies Clinical Pipeline by Phase (%), 2020 till 2027
Figure 11-2: Global – Cell Therapies Clinical Pipeline by Phase (Number), 2020 till 2027
Figure 11-3: Global – Cell Therapies Clinical Pipeline by Region (Number), 2020 till 2027
Figure 11-4: Global – Cell Therapies Clinical Pipeline by Company (Number), 2020 till 2027
Figure 11-5: Global – Cell Therapies Clinical Pipeline by Indication (Number), 2020 till 2027
Figure 11-6: Global – Cell Therapies Clinical Pipeline by Patient Segment (Number), 2020 till 2027
Figure 11-7: Global – Cell Therapies Clinical Pipeline by Route Of Administration (Number), 2020 till 2027

Figure 13-1: Global – COVID-19 Cell Therapies Clinical Pipeline by Phase (%), 2020
Figure 13-2: Global – COVID-19 Cell Therapies Clinical Pipeline by Phase (Number), 2020
Figure 13-3: Global – COVID-19 Cell Therapies Clinical Pipeline by Company (Number), 2020
Figure 13-4: Global – COVID-19 Cell Therapies Clinical Pipeline by Country (Number), 2020

Figure 15-1: Cell Therapy- The Final Therapeutic Pillar of Healthcare
Figure 15-2: Global – Cell Therapy Market (US$ Billion), 2019 – 2027
Figure 15-3: Process for Conventional Drug Delivery
Figure 15-4: Process for Induced Pluripotent Stem Cell Based Drug Delivery
Figure 15-5: Global- Induced Pluripotent Stem Cell Therapy Market (US$ Billion), 2019 – 2027
Figure 15-6: Steps involved in Bone Marrow Transplant

Figure 16-1: US – Allocord Infusion per Hour (Millilitres), Adult and Children
Figure 16-2: Allocord – Composition of Single Unit of Suspension for Injection (Million Cells)
Figure 16-3: Laviv – FDA Approval and Patent Expiration Year
Figure 16-4: Laviv – Cost of Single Treatment Cycle and Full Treatment Cost (US$), May’2020
Figure 16-5: MACI – Mixed Cell Populations for Tissue Repair and Separation Technique Related Patent Issue and Expiration Year
Figure 16-6: MACI – Administration Related Patent Issue and Expiration Year
Figure 16-7: MACI – Method of Manufacturing Related Patent Issue and Expiration Year
Figure 16-8: MACI – Cost for Treatment of Fractures and Cartilage Injury (US$), May’2020
Figure 16-9: MACI – Cost for Treatment of Fractures and Cartilage Injury (US$), May’2020
Figure 16-10: US – Clevecord Dosage of Nucleated Cells per Killogram (Million) and Average Cost (US$)
Figure 16-11: Hemacord – Composition of Single Unit of Suspension for Injection (Million Cells)
Figure 16-12: Ducord – Composition of Single Unit of Suspension for Injection (Million Cells)
Figure 16-13: Provenge – Patent Issue and Expiration Year
Figure 16-14: Provenge – Price of 250ml Supply and Price per ml (US$), May’2020
Figure 16-15: Provenge – Price of Single Treatment Cycle and Price for Full Treatment (US$), May’2020
Figure 16-16: HPC Cord Blood (Clinimmune Labs) – Composition of Single Unit of Suspension for Injection (Million Cells)
Figure 16-17: Kymriah – FDA Approval Year by Indication
Figure 16-18: Kymriah – Number of Patents by Region
Figure 16-19: Kymriah – Number of US Patents by Nature of Patent
Figure 16-20: US – Kymriah Average Dosage of CAR positive viable T cells (Paediatric and Adults), August 2017
Figure 16-21: Kymriah – Cost of Intravenous Suspension and Additional Expenditure (US$), May’2020
Figure 16-22: Kymriah – Minimum and Maximum Dose for Patients with Less than 50Kg Weight for ALL Management (Million Cells/ Kg), May’2020
Figure 16-23: Kymriah – Minimum and Maximum Dose for Management of Large B-Cell Lymphoma (Million Cells/ Kg), May’2020
Figure 16-24: Kymriah – Annual Sales Value (US$ Million), 2017 – 2019
Figure 16-25: Global – Kymriah Quarterly Sales Value (US$ Million), 2019
Figure 16-26: Yescarta – FDA Approval and US Patent Expiration Year
Figure 16-27: US – Yescarta Target Dose vs Maximum Dose of CAR-positive viable T cells, October 2017
Figure 16-28: Yescarta – Cost of Intravenous Suspension and Additional Expenditure (US$), May’2020
Figure 16-29: Yescarta – Dose for Average Human and Maximum Dose (Million Cells), May’2020
Figure 16-30: Yescarta – Annual Sales Value (US$ Million), 2017 – 2019
Figure 16-31: Yescarta – Annual Sales Value by Region (US$ Million), 2019
Figure 16-32: Yescarta – Annual Sales Value by Region (%), 2019
Figure 16-33: Global – Yescarta Quarterly Sales Value (US$ Million), 2018 and 2019
Figure 16-34: Carticel – FDA Approval and Patent Expiration Year
Figure 16-35: US – Carticel Minimum and Maximum Cost (US$), October 2017

Figure 17-1: Cartistem – Average Cost of Regenerative and Additional Treatment (US$), May’2020
Figure 17-2: Cartistem – Annual Sales Value (KRW/US$ Million), 2012 and 2019
Figure 17-3: Chondron – Average Cost of Knee Cartilage Defect Treatment (KRW/US$), May’2020
Figure 17-4: South Korea – KeraHeal vs KeraHeal-Allo Dosage form (Miililitres Cell Suspension)
Figure 17-5: Cellgram – Average Cost of Intravenous Suspension (KRW/US$), May’2020

Figure 18-1: Holoclar – Cost of Single and Both Eyes Treatment (GBP/US$), May’2020
Figure 18-2: Holoclar – Recommended Minimum and Maximum Dose (Cells/cm2 of Cornea Surface), May’2020
Figure 18-3: Yescarta – FDA Approval, EU Approval and US Patent Expiration Year
Figure 18-4: Yescarta – Cost of Intravenous Suspension and Additional Expenditure (EUR/US$), May’2020
Figure 18-5: Yescarta – Dose for Average Human and Maximum Dose (Million Cells), May’2020
Figure 18-6: Yescarta – Annual Sales Value (US$ Million), 2019′Q1 and 2020′Q1
Figure 18-7: Yescarta – Annual Sales Value (US$ Million), 2017 – 2019
Figure 18-8: Yescarta – Annual Sales Value by Region (US$ Million), 2019
Figure 18-9: Yescarta – Annual Sales Value by Region (%), 2019
Figure 18-10: Europe – Yescarta Quarterly Sales Value (US$ Million), 2019
Figure 18-11: Kymriah – FDA Approval Year by Region
Figure 18-12: Kymriah – Number of Patents by Region
Figure 18-13: Kymriah – Cost of Intravenous Suspension and Additional Expenditure (EUR/US$), May’2020
Figure 18-14: Kymriah – Minimum and Maximum Dose for Patients with Less than 50Kg Weight for ALL Management (Million Cells/ Kg), May’2020
Figure 18-15: Kymriah – Minimum and Maximum Dose for Management of Large B-Cell Lymphoma (Million Cells/ Kg), May’2020
Figure 18-16: Global – Kymriah Quarterly Sales Value (US$ Million), 2019′Q1 and 2020′Q1
Figure 18-17: Kymriah – Annual Sales Value (US$ Million), 2017 – 2019
Figure 18-18: Global – Kymriah Quarterly Sales Value (US$ Million), 2019
Figure 18-19: Japan – Temcell Dosage of Cells per Killogram Body Weight (Million)
Figure 18-20: Cost for Single Bag, Single Treatment Cycle and Full Treatment (JPY/US$), May’2020
Figure 18-21: Australia – Ortho-ACI Constituents of Dulbecco’s Modified Eagle Medium (DMEM) nutrient mixture
Figure 18-22: Australia – Ortho-ACI Average Dose (Million Cells) and Cost of Treatment (US$)

Figure 19-1: Significance of Cell Therapy Market Technology
Figure 19-2: Drivers for Growth of Cell Therapy in Japan
Figure 19-3: Criteria Impacting Successful Cell Therapy
Figure 19-4: China Cell Therapy Market Strategy
Figure 19-5: Rest of the World – Cell Therapy Clinical Trial by Region (%), 2019

Figure 20-1: Signaling Pathway in Chronic Lymphocytic Leukemia
Figure 20-2: Advantages of Treating Rheumatoid arthritis with Umbilical Cord
Mesenchymal Stem Cells
Figure 20-3: Stem Cell Therapy for the Treatment of Male Infertility
Figure 20-4: Cell Therapy for Ptients with Angina
Figure 20-5: Benefits of Stem Cell Therapy in Aesthetic Purposes

Figure 21-1: Working of CD4+ and CD25+ Regulatory T-Cell
Figure 21-2: Mechanism of Action of Treg Cell
Figure 21-3: Therapeutic Action of Treg Cell
Figure 21-4: Future Applications of Treg Cells

Figure 22-1: Growth Opportunities for Cell Therapy

Figure 24-1: Bone Therapeutics Clinical Pipeline
Figure 24-2: Celgene Clinical Pipeline
Figure 24-3: Cell Medica Therapeutics Clinical Pipeline
Figure 24-4: Cellerant Therapeutics Clinical Pipeline
Figure 24-5: Fibrocell Science Clinical Pipeline
Figure 24-6: Intrexon Clinical Pipeline
Figure 24-7: Mesoblast Clinical Pipeline
Figure 24-8: Molmed Clinical Pipeline
Figure 24-9: Tigenix Clinical Pipeline
Figure 24-10: Vericel Corporation Clinical Pipeline



★調査レポート[細胞治療の世界市場] (コード:HNI908SP2842)販売に関する免責事項を必ずご確認ください。
★調査レポート[細胞治療の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆